The coagulo-lytic system and endothelial function in cyclosporine- treated kidney allograft recipients

Transplantation

Volumn 62, Issue 6, 1996, Pages 828-830

  Malyszko, Jolanta ^a,b,c   Malyszko, Jacek S ^a   Pawlak, Krystyna ^a   Mysliwiec, Michal ^a  

^a Medical School   (Poland)

^b Pol Found for Research Development   (Poland)

^c MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; FIBRINOGEN; PLASMINOGEN; PREDNISONE; PROTEIN C; PROTHROMBIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; ALLOGRAFT; ARTICLE; CLINICAL ARTICLE; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; FIBRINOLYSIS; FUNCTION TEST; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL;

EID: 0029769508     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199609270-00021     Document Type: Article

References (29)

1. Vanrenterghem Y, Roels L, Lerut T, et al. Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients. Lancet 1985; i: 999.
2. Grace AA, Barradas MA, Mikhailidis DP, et al. Cyclosporine A enhances platelet aggregation. Kidney Int 1987; 32: 889.
3. Ross R. The pathogenesis of atherosclerosis: an update. N Engl J Med 1986; 314: 488.
4. Barnes JL, Ventakatachalam MA. The role of platelets and polycationic mediators in glomerular vascular injury. Semin Nephrol 1985; 5: 57.
5. Fellstrom B, Siegbahn A, Liljenberg G, et al. Primary haemostasis, plasmatic coagulation and fibrinolysis in renal transplantation. Thromb Res 1990; 59: 97.
6. Levi M, Wilmink J, Buller HR, Surachno J, Ten Cate JW. Impaired fibrinolysis in cyclosporine-treated renal transplant recipients. Transplantation 1992; 54: 978.
7. Cohen H, Neild GH, Mackie IJ, Machin SJ. Persistent decreased fibrinolytic activity in cyclosporine-treated renal allograft recipients. Fibrinolysis 1988; 2: 197.
8. Quick AJ. Haemorrhagic diseases and thrombosis. Philadelphia: Lea & Febiger, 1966.
9. Kowalski E, Kopec M, Niewiarowski S. An evaluation of the euglobulin method for determination of fibrinolysis. J Clin Pathol 1959; 12: 215.
10. Vaziri ND, Ismail M, Martin DC, Gonzales E. Blood coagulation, fibrinolytic and inhibitory profiles in renal transplant recipients: comparison of cyclosporine and azathioprine. Int J Artif Organs 1992; 15: 365.
11. Edwards CM, Morgan JDT, Donnelly PK. Cyclosporine-related hypercoagulability: fact or fiction? Transplant Proc 1992; 24: 2616.
12. Neild GH, Reuben R, Hartley RB, Cameron JS. Glomerular thrombi in renal allografts associated with cyclosporine treatment. J Clin Pathol 1985; 38: 253.
13. Bergstrand A, Bohman SO, Farnsworth A, et al. Renal histopathology in kidney transplant recipients immunosuppressed with cyclosporin A: results of an international workshop. Clin Nephrol 1985; 24: 107.
14. Bastida E, Escolar G, Ordinas A, Sixma JJ. Fibronectin is required for platelet adhesion and for thrombus formation on subendothelium and collagen surfaces. Blood 1987; 70: 1437.
15. Verstraete M, Vermylen J. Thrombosis, Oxford: Pergamon, 1984: 1.
16. Brown Z, Neild GH, Willoughby JJ, Somia NV, Cameron S. Increased factor VIII as an index of vascular injury in cyclo sporine nephrotoxicity. Transplantation 1986; 42: 150.
17. Cohen H, Neild GH, Patel R, Mackie IJ, Machin SJ. Evidence for chronic platelet hyperaggregability and in vivo activation in cyclosporine-treated renal allograft recipients. Thromb Res 1988; 49: 91.
18. Levin EG, Marzec U, Anderson J, Harker LA. Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells. J Clin Invest 1984; 74: 1988.
19. Juhan-Vague I, Alesssi MC. Plasminogen activator I and atherothrombosis. Thromb Haemostas 1993; 70: 138.
20. Angles-Cano E, Rondeau E, Delarue F, Hagage J, Sultan Y, Sraer J. Identification and cellular localization of plasminogen activators from human glomeruli. Thromb Haemostas 1985; 54: 688.
21. Hasui Y, Suzumiya J, Sumiyoshi A, Hashida S, Ishikawa E. Distribution of plasminogen activators in human kidney and male genital organs using a highly sensitive enzyme immunoassay. Thromb Res 1988; 51: 453.
22. Nilsson IM, Ljunger H, Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J 1985; 290: 1453.
23. Drouet L, Scrobohaci ML, Ghorra P, Baudin B, Gluckman E, Idatte JM. Clinical usefulness of plasmatic markers of the endothelial function: application to cyclosporin nephrotoxicity. Thromb Haemostas 1989; 62: 579.
24. Baker LRI, Tucker B, Kovacs IB. Enhanced in vitro hemostasis and reduced thrombolysis in cyclosporine-treated renal transplant recipients. Transplantation 1990; 49: 905.
25. Ljunger H, Berqvist D, Husberg B, Bergentz S. Decreased fibrinolytic activity in vessels and ureters of rejecting human kidneys. Scand J Urol Nephrol 1983; 17: 361.
26. Isacson S. Effect of prednisolone on the coagulation and fibrinolytic systems. Scand J Haematol 1970; 7: 212.
27. Frey FJ, Schaad HJ, Renner EL, Horber FF, Frey BM, Preisig R. Impaired liver function in stable renal allograft recipients. Hepatology 1989; 9: 606.
28. Hunt BJ, Segal H, Yacoub M. Hemostatic changes in heart transplant recipients and their relationship to accelerated coronary sclerosis. Transplantation 1993; 55: 309.
29. Edelberg JM, Pizzo SV. Lipoprotein (a) inhibits plasminogen activation in a template-dependent manner. Blood Coagul Fibrinol 1991; 2: 759.